ORIGINAL ARTICLE

A Gingiva-Derived Mesenchymal Stem Cell-Laden Porcine Small Intestinal Submucosa Extracellular Matrix Construct Promotes Myomucosal Regeneration of the Tongue

Qilin Xu, MD, PhD,^{1,*} Rabie M. Shanti, DMD, MD,^{1-3,*} Qunzhou Zhang, PhD,¹ Steven B. Cannady, MD,² Bert W. O'Malley Jr., MD,² and Anh D. Le, DDS, PhD^{1,3}

In the oral cavity, the tongue is the anatomic subsite most commonly involved by invasive squamous cell carcinoma. Current treatment protocols often require significant tissue resection to achieve adequate negative margins and optimal local tumor control. Reconstruction of the tongue while preserving and/or restoring its critical vocal, chewing, and swallowing functions remains one of the major challenges in head and neck oncologic surgery. We investigated the *in vitro* feasibility of fabricating a novel combinatorial construct using porcine small intestinal submucosa extracellular matrix (SIS-ECM) and human gingiva-derived mesenchymal stem cells (GMSCs) as a GMSC/SIS-ECM tissue graft for the tongue reconstruction. We developed a rat model of critical-sized myomucosal defect of the tongue that allowed the testing of therapeutic effects of an acellular SIS-ECM construct versus a GMSC/SIS-ECM construct on repair and regeneration of the tongue defect. We showed that the GMSC/SIS-ECM construct engrafted at the host recipient site, promoted soft tissue healing, and regenerated the muscular layer, compared to the SIS-ECM alone or nontreated defect controls. Furthermore, our results revealed that transplantation of the GMSC/SIS-ECM construct significantly increased the expression of several myogenic transcriptional factors and simultaneously suppressed the expression of type I collagen at the wounded area of the tongue. These compelling findings suggest that, unlike the tongue contracture and fibrosis of the nontreated defect group, transplantation of the combinatorial GMSC/SIS-ECM constructs accelerates wound healing and muscle regeneration and maintains the overall tongue shape, possibly by both enhancing the function of endogenous skeletal progenitor cells and suppressing fibrosis. Together, our findings indicate that GMSC/SIS-ECM potentially served as a myomucosal graft for tongue reconstruction postsurgery of head and neck cancer.

Keywords: gingiva-derived MSCs, SIS-ECM, combinatorial construct, wound healing, tongue regeneration, skeletal muscle progenitors, fibrosis

Introduction

WORLDWIDE, ORAL CANCER is the 6th and 12th most common cancer in men and women, respectively.^{1,2} Squamous cell carcinoma (SCC) accounts for 90% of oral cancers, while the tongue is the most frequently affected anatomic subsite.³ The current standard of care for primary invasive SCC of the oral tongue is tumor resection and neck dissection with the possibility for adjuvant radiotherapy and/or chemotherapy.^{4,5}

Even though treatment modalities for invasive tongue SCC have evolved over the past couple of decades, resection of any malignant neoplasm of the tongue remains an anatomically disfiguring, functionally debilitating, and psychologically impactful operation for the vast majority of patients.

Techniques that are available today for tongue reconstruction range from primary closure, healing by secondary intention, biologic skin substitutes, skin grafts, local and regional flaps to more sophisticated microvascular-free

¹Department of Oral and Maxillofacial Surgery and Pharmacology, University of Pennsylvania School of Dental Medicine, Philadelphia, Pennsylvania.

²Department of Otorhinolaryngology—Head and Neck Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

³Department of Oral and Maxillofacial Surgery, Penn Medicine Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.

*These authors contributed equally to this work.

tissue transfer flaps.⁶ The ultimate goal of tongue reconstruction irrespective of etiology is to restore the integrity of the tongue while preserving its critical functions (i.e., articulation, mastication, deglutition) and minimize the morbidity profile of a selected reconstructive technique.⁷

Through decades of evolution in reconstructive principles and techniques, microvascular-free tissue transfer has evolved as the reconstructive technique of choice following extirpation of malignant neoplasms.⁸ Soft tissue-free flaps, such as the radial forearm-free flap and the anterolateral thigh-free flap, have opened up new avenues for improving tongue reconstruction outcomes based on their tissue bulk and versatility of flap inset that limit tethering of the tongue and, if necessary, allowing for composite tissue replacement.^{8,9} However, these flaps, made up of skin, subcutaneous adipose tissue, and fascia, do not allow for the restoration of muscular-like tissue. Furthermore, harvesting these flaps will always result in donor site morbidity that will cause some degrees of local pain, edema, limb weakness, and scar formation.

Implant transplantation has been explored as another reconstructive option. Of particular interest is the ability to implant biological materials that promote tongue tissue regeneration with resultant biological tissues representing normal tongue anatomy that is devoid of fibrosis. Even though various combinations of implants have been used, treatment outcomes are still suboptimal.^{10,11} A candidate implant is the porcine small intestinal submucosa extracellular matrix (SIS-ECM), which has been shown to promote tissue-specific growth and differentiation across various applications.¹²

Multiple studies have demonstrated that SIS-ECM contains key ECM components and growth factors necessary for normal tissue regeneration, such as collagen, proteoglycan glycosaminoglycan, glycoprotein, vascular endothelial growth factor (VEGF),¹³ transforming growth factor-beta (TGF- β), basic fibroblast growth factor (bFGF), and epidermal growth factor (EGF).¹⁴ SIS has been tested in animals to successfully repair urinary bladder,¹⁵ abdominal body wall defects,¹⁶ and esophageal,¹⁷ tracheal,¹⁸ cardiovascular,¹⁹ partial- and full-thickness skin defects.²⁰ More importantly, as a product approved by the U.S. Food and Drug Administration (FDA), this biomaterial has been applied to over 1 million patients for the repair of a variety of tissue defects.^{21–29} These studies have demonstrated the compatibility of SIS-ECM with host tissues by not only providing structural support but also promoting the regenerative responses of the host during the tissue repairing process.

Mesenchymal stem cells (MSCs) represent a subpopulation of multipotent stromal cells that reside in almost all adult tissues and are capable of differentiating into several different cell lineages, escaping allogeneic immune responses, and also possess potent immunomodulatory and anti-inflammatory functions.^{30,31} Accumulating evidence suggests that both endogenous and exogenous MSCs are capable of sensing their microenvironment and migrating to injured sites where they interact with other types of structural and immune cells to orchestrate the complex site-specific tissue repair process.^{30,32} These unique properties make MSCs a unique candidate cell source for stem cell-based therapy in a wide range of clinical scenarios, including the tissue engineering/regeneration of various types of tissues and organs.^{30,32,33}

Recent studies have shown that SIS-ECM could be an ideal scaffold for effective delivery of MSCs, whereby combina-

torial use of SIS-ECM and MSCs exhibited improved regenerative outcome in skin wound healing and a variety of tissue defects, including cardiovascular,¹⁹ urinary bladder, vocal fold,³⁴ tracheal,¹⁸ muscle, and bone tissues.^{18,19,20,34–37} However, little is known about the potential application of SIS-ECM alone or in combination with MSCs in repair/regeneration of critical-sized tongue defects.

Our group has isolated and characterized a unique population of gingiva-derived MSCs (GMSCs), which showed a high proliferation rate, multipotent differentiation potential, and potent immunomodulatory/anti-inflammatory functions.^{38,39} We have also shown that the systemic administration of GMSCs could promote skin wound healing and mitigate chemotherapy-induced oral mucositis.^{40,41} In this study, we developed a rat model of critical-sized myomucosal defect of the tongue, which allows us to test the therapeutic effects of the combinatorial GMSC/SIS-ECM constructs on repair and regeneration of the tongue.

Materials and Methods

Animals

Female Sprague-Dawley rats weighing 200–250 g (6–7 weeks old) (Charles River Laboratories, Wilmington, MA) were used in this study. All animal procedures were handled according to the guidelines of the Institutional Animal Care and Use Committee (IACUC) of the University of Pennsylvania. We adopted a randomized, prospective, and controlled animal model design according to all the recommendations of the ARRIVE (Animal Research: Reporting *In Vivo* Experiments) guidelines. Rats were group-housed in polycarbonate cages (three animals per cage) in the animal facilities with controlled temperature ($23^{\circ}\text{C} \pm 2^{\circ}\text{C}$), 40–65% of humidity, and a 12-h light/12-h dark cycle. Rats were acclimatized for at least 1 week before the study, fed with a standard laboratory diet, and allowed *ad libitum* access to drinking water.

Cell cultures

Gingival tissues were obtained as remnants of discarded tissues from healthy human subjects who underwent routine dental procedures under the approved Institutional Review Board (IRB) protocol at the University of Pennsylvania. The gingiva-derived mesenchymal stem cells (GMSCs) were isolated and cultured according to methods as we previously described.³⁸ Primary cells were cultured and *ex vivo* expanded in complete growth medium consisting of alpha-MEM supplemented with 1% L-glutamine, 10% FBS, and 1% penicillin/streptomycin at 37°C with 5% CO_2 . Cells with 80% confluence were passaged using 0.05% Trypsin-EDTA solution (Life Technology, Carlsbad, CA). Cells <6 passages were used for experiments.

SIS-ECM construct preparation

A novel combined construct was generated using an FDA-approved decellularized porcine small intestinal submucosa extracellular matrix (SIS-ECM 2.0) (Cook Biotech, Inc., West Lafayette, IN)⁴² seeded with human gingiva-derived mesenchymal stem cells (GMSCs). Prelabeling of GMSCs with PKH26 fluorescein dye (Sigma-Aldrich, St. Louis, MO) was performed according to the manufacturer's instructions. Then, 5×4 mm strips of SIS-ECM membranes were soaked

in serum-free medium for 24 h, and GMSCs (3.5×10^5 cells/cm²) prelabeled with PKH26 were seeded onto the mucosal side of the SIS-ECM and cultured for 48 h at 37°C with 5% CO₂ before being transplanted into the defected tongues of rats. SIS-ECM membranes soaked in serum-free medium for 24 h without seeded GMSCs were used as controls.

Animal surgery

Animals were anesthetized with intraperitoneal injection of ketamine/xylazine (100/10 mg/kg) followed by injection of 0.1 mL of 1% lidocaine with 1:100,000 epinephrine into the left hemitongue for local vasoconstriction. All rats underwent a left-sided anterior defect by way of a lateral approach. A tongue wound was created using a 6-mm biopsy

punch (Miltex, Inc., York, PA) in the left side of anterior dorsal tongue surface at the depth (3 mm) of the muscle layers to damage both the epithelium and the stroma.

Animals were randomly divided into the following groups ($n=6$ /group): (1) Tongue defect; (2) Tongue defect transplanted with SIS-ECM; (3) Tongue defects transplanted with SIS-ECM seeded with GMSCs prelabeled with PKH26 (GMSC/SIS-ECM). The SIS-ECM constructs were patched over the wound, with the cell-seeded side oriented toward the wounded muscle layers. Then, 8–0 Ethilon (Ethicon, Inc., Somerville, NJ) interrupted sutures were applied to secure the construct. The entire procedure was performed under a surgical microscope (Global Surgical Corporation, St. Louis, MO).

At days 0, 1, 3, 5, 7 following surgery, the wounds were photographed using a Nikon D90 digital camera with an AF

FIG. 1. Integration of GMSC/SIS-ECM constructs with host tissues and promotes tongue wound healing. (A) The distribution of GMSCs seeded in GMSC/SIS-ECM constructs after culture for 48 h. GMSCs were double stained with PKH26 (red) and anti-CD90 (green) antibody and observed under a fluorescence microscope. The nuclei were counterstained with DAPI. (B) Tongue defects photographed at day 0, 3, 5, and 7 after the surgery. There was no infection at the surgery site in all three groups. SIS-ECM scaffold was dissolved around day 5. Blue circle indicates the area of the defect at day 7 postsurgery. The tongue wound areas for both SIS-ECM and GMSC/SIS-ECM groups were smaller than the defect control group. (C) Measurement of the wound area of each group postsurgery at day 3, 5, and 7 relative to that at day 0. Data show GMSC/SIS-ECM group had a faster wound healing rate than SIS-ECM and control groups. (D) Measurement of the body weight of each group postsurgery at day 1, 3, 6, 9, and 12. Data show all groups were able to maintain appropriate body weight. (E) Tongue defects photographed at 2 weeks after surgery. Blue circle indicates the area of the defect at day 7. (F) H&E staining results of cross sections of specimens from control, SIS-ECM only and GMSC/SIS-ECM construction groups after 2 weeks of surgery (original magnification $\times 10$). DAPI, 4',6'-diamidino-2-phenylindole; GMSC, gingiva-derived mesenchymal stem cell; H&E, hematoxylin and eosin; SIS-ECM, small intestinal submucosa extracellular matrix.

Micro NIKKOR 60 mm lens. The images were uploaded to a computer and opened with Olympus cellSens™ imaging software (Olympus America, Inc., Center Valley, PA). For each photographic image, measurements were calibrated using a ruler at the base of the image included in the photographic frame. The wound margins were defined and traced from the photographic images, and the wound areas were calculated as a percent area of the original wound at day 0.^{43,44} On day 14 and 28 postsurgery, rats from each group were sacrificed and the tongues were harvested by transection at the circumvallate papillae and subsequently prepared for histological and immunohistochemical analysis.

Histological and immunofluorescence studies

The tongue samples were fixed in 10% neutralized formalin for 48 h and 5- μ m-thick paraffin sections and 8- μ m-thick cryosections were cut, respectively. Hematoxylin and eosin staining was performed according to the standard procedures, while Trichrome staining of collagens was performed using a Trichrome Stain Kit for connective tissue stain according to the manufacturer's procedures (Abcam, Cambridge, MA).

For immunofluorescence studies, the cryosections were permeabilized and blocked in PBS with 3% bovine serum albumin and 0.5% Triton X-100 at room temperature for 1 h. Then, the sections were incubated with primary antibodies for MyoD, Myf5 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), or PAX7 (R&D Systems, Inc., Minneapolis, MN) (1:250) overnight at 4°C, followed by incubation with FITC-

conjugated secondary antibodies for 1 h at room temperature. Isotype-matched control antibodies (BioLegend, Inc., San Diego, CA) were used as negative controls. Nuclei were counterstained with 4',6'-diamidino-2-phenylindole (DAPI) (Life Technologies), and slides were observed under a fluorescence microscope (Olympus IX-73). The integrated immunofluorescence density of a region of interest (ROI) was quantified using Olympus cellSens imaging software.

Western blotting

Equal amount of protein samples (30 μ g) from the injured areas of the tongue was separated on 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and electroblotted onto nitrocellulose membrane (Bio-Rad, Hercules, CA). After blocking with TBS/5% nonfat dry milk, the membrane was incubated with antibodies against MYOD, PAX7, and MYF5 (1:1000) followed by incubation with a horseradish peroxidase (HRP)-conjugated secondary antibody, and the signals were visualized by enhanced chemiluminescence detection (Thermo Scientific). The blots were also reprobbed with a specific antibody against β -actin (Sigma) as internal controls.

Statistical analyses

Differences between experimental and control groups were analyzed by the paired Student's *t*-test. One-way analysis of variance was used to test the statistical significance of multiple

FIG. 2. Engraftment of Transplanted GMSCs at the Wound Site and Expression of Myogenic Transcriptional Factors. (A) H&E staining results of cross section of specimen taken after GMSC/SIS-ECM construction implantation at 2 weeks. Blue circle indicates the area of myomucosal regeneration. Muscle regeneration was not identified until 2 weeks in all groups (original magnification $\times 4$). The distribution of PKH26 prelabeled GMSCs at the circled regeneration area was observed under a fluorescence microscope (original magnification $\times 10$). The nuclei were counterstained with DAPI. Coexpression of MyoD (green) (B), Myf5 (green) (C), PAX7 (green) (D), and PKH26 (red) in GMSCs at local defect area after 2 weeks transplantation was determined by immunostaining and observed under a fluorescence microscope. The nuclei were counterstained with DAPI (original magnification $\times 20$).

group differences, unless otherwise indicated. *Post hoc* pairwise comparison between individual groups was made using the Tukey test. *p*-Values <0.05 were considered statistically significant. SPSS software was used for all the analyses. All data are expressed as mean $\pm$ standard deviation (S.D.).

Results

Generation of combinatorial constructs of GMSC/SIS-ECM

Human gingiva-derived mesenchymal stem cells (GMSCs) used in this study were isolated and characterized according to the expression of a panel of cell surface markers (CD29, CD44, CD73, CD90) but negative for hematopoietic and endothelial cell surface markers and their multipotent differentiation capabilities as previously described.³⁸ To fabricate the combinatorial construct, GMSCs prelabeled with PKH26 were seeded onto the mucosal side of the decellularized SIS-ECM scaffold at a cell density of 3.5×10^5 cells/cm² according to a previous report.¹⁹ After culture for 48 h, the constructs were harvested and immunofluorescence staining showed that a confluent monolayer of GMSCs adhered on SIS-ECM scaffold and positively expressed CD90 (Fig. 1A).

Integration of GMSC/SIS-ECM constructs with host tissues promotes tongue wound healing

We then transplanted the SIS-ECM scaffold seeded with (GMSC/SIS-ECM) or without GMSCs onto the critical-sized tongue defects and observed the wound healing process at different time points. All rats were able to survive after the surgical insult and tolerate the defect while maintaining appropriate body weight (Fig. 1D).

Our results indicated that the transplanted SIS-ECM scaffold was completely resorbed by day 7 after transplantation (Fig. 1B). The wound healing rate is defined as the gross epithelialization of the wound defect area.⁴⁵ Until day 5 postsurgery, no obvious differences in the wound healing rate were observed among different groups (Fig. 1B). However, by day 7 postsurgery, the tongue wound areas for both SIS-ECM and GMSC/SIS-ECM groups were smaller than the defect control group; whereby, the GMSC/SIS-ECM group had a faster wound healing rate than SIS-ECM group ($p < 0.05$) (Fig. 1C).

By day 14 postsurgery, clinical morphology of tongue indicated that both SIS-ECM and GMSC/SIS-ECM groups showed less scarring and wound contracture and maintained the overall tongue shape without deformity compared to the defect control, whereas GMSC/SIS-ECM group displayed better tissue restoration than transplantation of SIS-ECM

FIG. 3. Increased expression of MyoD and PAX7 in both wounded tongue areas with transplantation of GMSC/SIS-ECM and SIS-ECM in comparison with defect control. Expression of MyoD (green) (A) and PAX7 (green) (D) at local defect area 2 weeks after surgery in control, SIS-ECM only and GMSC/SIS-ECMs construct groups were determined by immunostaining and observed under a fluorescence microscope. The nuclei were counterstained with DAPI (original magnification $\times 10$; $\times 20$). The integrated immunofluorescence density of a ROI for both MyoD (B) and PAX7 (E) was quantified using Olympus cellSens™ imaging software. (C, F) The expression of MyoD and PAX7 proteins at the injured areas of the tongue was determined by Western blot analysis. ROI, region of interest.

scaffold alone (Fig. 1E). Histological analysis showed complete reepithelialization throughout all groups, but GMSC/SIS-ECM group showed apparent muscle regeneration compared with SIS-ECM alone and defect control groups (Fig. 1F). These findings suggest that the combinatorial GMSC/SIS-ECM constructs are capable to regenerate, in some extent, some specialized tissue components, specifically the muscle layer, compared to SIS-ECM scaffold alone or nontreated defect control.

Engraftment of transplanted GMSCs at the wound site

We next determined whether PKH26 prelabeled GMSCs transplanted with SIS-ECM scaffold engrafted at the wound defect sites following transplantation. At day 14 post-transplantation of the PKH26-labeled GMSC/SIS-ECM construct, frozen sections were harvested and immunostained with antibodies for MyoD, Myf5, and PAX7, three myogenic transcription factors.^{46,47} Using immunofluorescent studies, we showed that PKH26 labeled GMSCs transplanted with SIS-ECM scaffold engrafted at the deep muscle layer of the tongue defect (Fig. 2A); ~10% engrafted PKH26 labeled GMSCs harbored overlapping green signals that represent the positive expression of MyoD, Myf5, or PAX7 (Fig. 2B–D). These find-

ings suggest that a small proportion of transplanted GMSCs engrafted at the deep muscle layer of the critical tongue defect and were able to differentiate into myoblast progenitor-like cells.

Transplantation of GMSC/SIS-ECM constructs increased the expression of myogenic transcriptional factors

We next determined the effect of transplantation of GMSC/SIS-ECM constructs on the expression of myogenic transcriptional factors, MyoD, Myf5, and PAX7, in the wounded defect area of the tongue on day 14 postsurgery.

Our results showed that transplantation of both SIS-ECM alone and GMSC/SIS-ECM significantly increased the expression of MyoD and PAX7, but the effect conferred by the combinatorial GMSC/SIS-ECM constructs was more pronounced than the SIS-ECM scaffold alone (Fig. 3A, B, D, E). In addition, we found that transplantation of the combinatorial GMSC/SIS-ECM constructs, but not the SIS-ECM scaffold alone, led to a robust increase in the expression of Myf5 (Fig. 4A, B). The increased expression of these myogenic transcriptional factors induced by transplantation of the combinatorial

FIG. 4. Increased expression of Myf5 in wounded tongue areas with transplantation of GMSC/SIS-ECM in comparison with SIS-ECM alone and defect control. (A) Expression of Myf5 (green) at local defect area 2 weeks after surgery in control, SIS-ECM only, and GMSC/SIS-ECM construct groups was determined by immunostaining and observed under a fluorescence microscope. The nuclei were counterstained with DAPI (original magnification $\times 10$; $\times 20$). (B) The integrated immunofluorescence density of a ROI was quantified using Olympus cellSens imaging software. (C) The expression of Myf5 protein at the injured areas of the tongue was determined by Western blot analysis.

GMSC/SIS-ECM constructs was further confirmed by Western blot analysis (Figs. 3C, F and 4C).

These findings further support the notion that transplantation of the combinatorial GMSC/SIS-ECM constructs not only accelerates tongue wound healing but also induces muscle regeneration, possibly by enhancing the function of endogenous skeletal progenitor cells.

Transplantation of GMSC/SIS-ECM constructs decreased the expression of type I collagen

Previous studies have shown that MSCs promote skeletal muscle regeneration and functional recovery by inhibiting fibrosis and remodeling scar tissues.^{33,48} We then examined the expression of type I collagen in the wounded defect areas of tongue at day 14 following transplantation. The results showed that transplantation of the combinatorial GMSC/SIS-

ECM constructs, but not SIS-ECM scaffold alone, significantly suppressed the expression of type I collagen at the wound defect areas (Fig. 5A, B). Trichrome staining of collagens showed similar findings (Fig. 5C, D). These findings were in accordance with the clinical observation showing decreased wound contracture and scar fibrosis at the tongue defect site grafted with the GMSC/SIS-ECM construct (Fig. 1D).

To further determine the anti-fibrotic effects conferred by transplantation of GMSC/SIS, we prolonged our observation up to 4 weeks postsurgery. Clinical morphology of tongue indicated that GMSC/SIS-ECM groups showed much less scarring and wound contracture and maintained the overall tongue shape without deformity compared to the defect control and SIS-ECM scaffold alone groups (Fig. 6A). Histological analysis indicated that GMSC/SIS-ECM group showed apparent muscle regeneration compared with SIS-ECM alone and defect control groups (Fig. 6B). Both

FIG. 5. Decreased expression of collagen I in defected tongue areas with transplantation of GMSC/SIS-ECM in comparison with SIS-ECM alone and defect control. Expression of Col-I (green) at local defect area 2 weeks after surgery in control, SIS-ECM only, and GMSC/SIS-ECM construct groups was determined by immunostaining and observed under a fluorescence microscope. The nuclei were counterstained with DAPI (A). The integrated immunofluorescence density of a ROI was quantified using Olympus cellSens imaging software (B) (original magnification $\times 10; \times 20$). The collagen deposition in defected areas of tongue was evaluated by trichrome staining (C), which was quantified using Olympus cellSens imaging software (D) (original magnification $\times 20$).

FIG. 6. Decreased expression of collagen I in defected tongue areas with transplantation of GMSC/SIS-ECM in comparison with SIS-ECM alone and defect control. **(A)** Tongue defects photographed at 4 weeks after surgery. *Yellow circle* indicates the area of the defect at day 28. **(B)** H&E staining results of cross sections of specimens from control, SIS-ECM only, and GMSC/SIS-ECM construction groups after 4 weeks of surgery (original magnification $\times 10$). The collagen deposition in defected areas of tongue was evaluated by trichrome staining **(C)**, which was quantified using Olympus cellSens imaging software **(D)** (original magnification $\times 20$). Expression of Col-I (*green*) at local defect area 4 weeks after surgery in control, SIS-ECM only, and GMSC/SIS-ECM construct groups was determined by immunostaining and observed under a fluorescence microscope. The nuclei were counterstained with DAPI **(E)** (original magnification $\times 10$). The integrated immunofluorescence density of a ROI was quantified using Olympus cellSens imaging software **(F)**.

trichrome staining (Fig. 6C, D) and immunofluorescence studies (Fig. 6E, F) indicated that GMSC/SIS-ECM group had less collagen deposition and type I collagen expression in defected areas of tongue in comparison to the defect control and SIS-ECM scaffold alone groups.

Altogether, the data suggest that transplantation of GMSC/SIS-ECM constructs not only promote tongue wound healing but also induce muscle regeneration, at least in part, through suppressing the fibrotic process.

Discussion

Reconstruction of tongue defects after ablative surgery of oral cancer remains a major challenge because of the

highly specialized and important functions of the tongue.⁴⁹ The current “work-horse” option for tongue reconstruction is vascularized-free flaps of soft tissues, which aim to minimize tethering of the tongue while also providing enough tissue bulk.⁵⁰ However, these reconstructive modalities have significant limitations and typically result in some degree of life-altering dysfunction in mastication, speech, swallowing, cosmetic deformities, and psychological effects.^{50,51} The overall lack of tissue-specific donor sites, severe tissue loss, and wound contracture lead to compromised oral function and a major decrease in the quality of life of patients, which then represents an unmet clinical need in patients with benign and malignant neoplasms of the tongue.

In recent years, novel tissue engineering/regenerative medicine (TE/RM) techniques have received increasing attention for reconstruction of volumetric muscle loss.^{52–54} The TE/RM approaches that aim to restore or reconstruct damaged tissues typically involve the use of cells, bioactive materials, and biologic or synthetic scaffolds. Among all these biological materials, a variety of naturally occurring decellularized extracellular matrix (ECM) scaffold materials have been widely appreciated for the signals and molecules they provided that can augment many aspects of cell behaviors, thus facilitating skeletal muscle reconstruction/regeneration.^{52,54}

The decellularized gastrointestinal small intestine submucosa (SIS) is among the most commonly used acellular scaffolds that display a comparable level of skeletal muscle regenerative capacity to a skeletal muscle-derived decellularized ECM.^{28,53–55} The pre- and clinical successful use of SIS-ECM in tissue reconstruction might be due to its special three-dimensional ECM structure,⁵⁶ components of inherent bioactive molecules,⁵⁷ and the biodegradability that can foster its integration with host tissues.⁵⁸ In addition, matrix-derived cell signaling molecules, including certain cytokines and growth factors, may play an important role in modulating fibrosis,²⁰ inflammation,^{59,60} angiogenesis,^{13,56,61,62} and other pathophysiological processes that are critical for tissues to initiate an optimal regenerative response.

Although SIS-ECM scaffolds have great advantages for tissue reconstruction in mechanical properties and structural integrity, they have a limited ability on their own to regenerate complex tissue structures such as the tongue. The success of the regenerative process depends upon the extent of initial damage and a myriad of other intrinsic and environmental factors. In the last decade, the introduction of stem cells into TE/RM field has resulted in significant strides in the regeneration of various functional tissues, including functional skeletal muscle.⁵⁴ A combinatorial or hybrid construct composed of acellular scaffold and stem cells may represent a new generation of biomaterials for skeletal muscle regeneration.⁵²

Several lines of evidence have shown an improved regenerative efficacy of the combined use of SIS-ECM and MSCs in a variety of animal models of tissue defects.^{18,19,20,34–37} Due to their potent multipotent differentiation capability and, more importantly, their secretion of a myriad of trophic factors with diverse biological functions, including immunomodulatory/anti-inflammatory, proliferative/antiapoptotic, proangiogenic, and antifibrotic functions, MSCs represent a promising candidate cell source for tissue regeneration.^{30,63,64}

Under several pathological settings, including skin wound,^{40,65} fibrotic lung disease,⁶⁶ liver fibrosis,⁶⁷ and muscle injury,^{34,48} the antifibrotic effects might be one of the most important machineries by which MSCs promote tissue repair/regeneration. Of note, the mechanisms underlying MSC-mediated antifibrotic effects are multiple facets, which may involve their secretion of various anti-inflammatory mediators to inhibit the activation of both innate and adaptive immune cells and boost the function of regulatory T cells and polarization of anti-inflammatory M2 macrophages, thus facilitating the resolution of local inflammation and ultimately alleviating fibrosis. On the contrary, MSCs may directly inhibit myofibroblast activation by secreting a panel of antifibrotic factors to curb the profibrotic signaling pathways, such as TGF- β /Smads.^{65,66}

Recently, we have shown that administration of GMSCs could promote skin wound healing by facilitating the

polarization of anti-inflammatory M2 macrophages at the wound site.⁴⁰ However, the complicated mechanisms by which MSCs attenuate fibrosis under different pathological settings are still not completely understood.⁶⁷

To the best of our knowledge, in the current study, we have shown for the first time that transplantation of combinatorial GMSC/SIS-ECM constructs exhibited better effects on accelerating tongue myomucosal regeneration in rats than transplantation of SIS-ECM alone, which was clinically presented as faster wound closure, less scarring, and less wound contraction. Our results also showed that transplanted GMSCs engrafted in the injured deep muscle layers of the tongue, but only a small portion of them ($\sim 10\%$) exhibited colocalized signals for positive expression of several key myogenic transcriptional factors, MyoD, Myf5, and PAX7. However, transplantation of combinatorial GMSC/SIS-ECM constructs significantly increased MyoD, Myf5, and PAX7 expression in host skeletal progenitor cells while it decreased the expression of type I collagen at the defect area of the tongue.

In summary, our findings suggest that transplanted GMSCs enhance tongue myomucosal regeneration probably by their anti-fibrotic effects as well as through their indirect paracrine effects on the activity and function of endogenous myoblast progenitor cells.⁴⁸ However, further studies are warranted to elucidate the cellular and molecular mechanisms by which GMSCs remodel scar/fibrosis and regulate the function of endogenous myoblast progenitor cells to facilitate tongue regeneration.

Acknowledgments

This study was supported by a research grant from National Institute of Health Research Grant (R01DE 019932, A.D.L.), the Oral and Maxillofacial Surgery Foundation Research Support Grant (to Q.X. and L. Carrasco), OsteoScience Foundation (to Q.Z.), and the Schoenleber funding support (to A.D.L.).

Authors' Contributions

Conception and design: A.D.L., Q.X., Q.Z., B.W.O. Jr.; Acquisition of data: Q.X., Q.Z.; Analysis and interpretation of data: Q.X., R.M.S., Q.Z.; Writing, review, and/or revision of the article: Q.X., R.M.S., Q.Z., S.B.C., B.W.O. Jr., A.D.L.; Study Supervision: A.D.L.

Disclosure Statement

No competing financial interests exist.

References

- Kim, K.Y., Li, S., Cha, J.D., Zhang, X., and Cha, I.H. Significance of molecular markers in survival prediction of oral squamous cell carcinoma. *Head Neck* **34**, 929, 2012.
- Cadier, M.A., Kelly, S.A., Parkhouse, N., and Brough, M.D. Basaloid squamous carcinoma of the buccal cavity. *Head Neck* **14**, 387, 1992.
- Ye, H., Yu, T., Temam, S., Ziober, B.L., Wang, J., Schwartz, J.L., Mao, L., Wong, D.T., and Zhou, X. Transcriptomic dissection of tongue squamous cell carcinoma. *BMC Genomics* **9**, 69, 2008.
- D'Cruz, A.K., Vaish, R., Kapre, N., Dandekar, M., Gupta, S., Hawaldar, R., Agarwal, J.P., Pantvaidya, G., Chaukar,

- D., Deshmukh, A., Kane, S., Arya, S., Ghosh-Laskar, S., Chaturvedi, P., Pai, P., Nair, S., Nair, D., Badwe, R.; Head, and Neck Disease Management Group. Elective versus therapeutic neck dissection in node-negative oral cancer. *N Engl J Med* **373**, 521, 2015.
5. Omura, K. Current status of oral cancer treatment strategies: surgical treatments for oral squamous cell carcinoma. *Int J Clin Oncol* **19**, 423, 2014.
6. Gurtner, G.C., and Evans, G.R. Advances in head and neck reconstruction. *Plast Reconstr Surg* **106**, 672, 2000.
7. Rigby, M.H., and Taylor, S.M. Soft tissue reconstruction of the oral cavity: a review of current options. *Curr Opin Otolaryngol Head Neck Surg* **21**, 311, 2013.
8. Engel, H., Huang, J.J., Lin, C.Y., Lam, W., Kao, H.K., Gazyakan, E., and Cheng, M.H. A strategic approach for tongue reconstruction to achieve predictable and improved functional and aesthetic outcomes. *Plast Reconstr Surg* **126**, 1967, 2010.
9. Brody, R.M., Pandey, N.C., Bur, A.M., O'Malley, B.W., Jr., Rassekh, C.H., Weinstein, G.S., Chalian, A.A., Newman, J.G., and Cannady, S.B. Anterior lateral thigh osteomyocutaneous free flap reconstruction in the head and neck: the anterolateral thigh osteomyocutaneous femur bone flap. *Head Neck* **38**, 1788, 2016.
10. Kim, J., Hadlock, T., Cheney, M., Varvares, M., and Marler, J. Muscle tissue engineering for partial glossectomy defects. *Arch Facial Plast Surg* **5**, 403, 2003.
11. Bunaprasert, T., Hadlock, T., Marler, J., Kobler, J., Cowan, D., Faquin, W., and Varvares, M. Tissue engineered muscle implantation for tongue reconstruction: a preliminary report. *Laryngoscope* **113**, 1792, 2003.
12. Voytik-Harbin, S.L., Brightman, A.O., Waisner, B.Z., Robinson, J.P., and Lamar, C.H. Small intestinal submucosa: a tissue-derived extracellular matrix that promotes tissue-specific growth and differentiation of cells in vitro. *Tissue Eng* **4**, 157, 1998.
13. Hodde, J.P., Record, R.D., Liang, H.A., and Badylak, S.F. Vascular endothelial growth factor in porcine-derived extracellular matrix. *Endothelium* **8**, 11, 2001.
14. Voytik-Harbin, S.L., Brightman, A.O., Kraine, M.R., Waisner, B., and Badylak, S.F. Identification of extractable growth factors from small intestinal submucosa. *J Cell Biochem* **67**, 478, 1997.
15. Caione, P., Capozza, N., Zavaglia, D., Palombaro, G., and Boldrini, R. In vivo bladder regeneration using small intestinal submucosa: experimental study. *Pediatr Surg Int* **22**, 593, 2006.
16. Lopes, M.F., Cabrita, A., Ilharco, J., Pessa, P., and Patrício, J. Grafts of porcine intestinal submucosa for repair of cervical and abdominal esophageal defects in the rat. *J Invest Surg* **19**, 105, 2006.
17. Lopes, M., Cabrita, A., Ilharco, J., Pessa, P., Paiva-Carvalho, J., Pires, A., and Patrício, J. Esophageal replacement in rat using porcine intestinal submucosa as a patch or a tube-shaped graft. *Dis Esophagus* **19**, 254, 2006.
18. Du, X.F., Kwon, S.K., Song, J.-J., Cho, C.G., and Park, S.-W. Tracheal reconstruction by mesenchymal stem cells with small intestine submucosa in rabbits. *Int J Pediatr Otorhinolaryngol* **76**, 345, 2012.
19. Chang, C.W., Petrie, T., Clark, A., Lin, X., Sondergaard, C.S., and Griffiths, L.G. Mesenchymal stem cell seeding of porcine small intestinal submucosal extracellular matrix for cardiovascular applications. *PLoS One* **11**, e0153412, 2016.
20. Lam, M.T., Nauta, A., Meyer, N.P., Wu, J.C., and Longaker, M.T. Effective delivery of stem cells using an extracellular matrix patch results in increased cell survival and proliferation and reduced scarring in skin wound healing. *Tissue Eng Part A* **19**, 738, 2013.
21. Edelman, D.S., and Selesnick, H. "Sports" hernia: treatment with biologic mesh (Surgisis)—a preliminary study. *Surg Endosc* **20**, 971, 2006.
22. Ding, J.X., Chen, X.J., Zhang, X.Y., Zhang, Y., and Hua, K.Q. Acellular porcine small intestinal submucosa graft for cervicovaginal reconstruction in eight patients with malformation of the uterine cervix. *Hum Reprod* **29**, 677, 2014.
23. Boyd, W.D., Johnson, W.E., Sultan, P.K., Deering, T.F., and Matheny, R.G. Pericardial reconstruction using an extracellular matrix implant correlates with reduced risk of postoperative atrial fibrillation in coronary artery bypass surgery patients. *Heart Surg Forum* **13**, E311, 2010.
24. Pokrywczynska, M., Adamowicz, J., Sharma, A.K., and Drewa, T. Human urinary bladder regeneration through tissue engineering—an analysis of 131 clinical cases. *Exp Biol Med* **239**, 264, 2014.
25. Nevins, M., Nevins, M.L., Camelo, M., Camelo, J.M.B., Schupbach, P., and Kim, D.M. The clinical efficacy of DynaMatrix extracellular membrane in augmenting keratinized tissue. *Int J Periodont Rest* **30**, 151, 2010.
26. Fan, M.R., Gong, M., Da, L.C., Bai, L., Li, X.Q., Chen, K.F., Li-Ling, J., Yang, Z.M., and Xie, H.Q. Tissue engineered esophagus scaffold constructed with porcine small intestinal submucosa and synthetic polymers. *Biomed Mater* **9**, 2014.
27. Pitman, M.J., Cabin, J.A., and Iacob, C.E. Small intestinal submucosa implantation for the possible treatment of vocal fold scar, sulcus, and superficial lamina propria atrophy. *Ann Oto Rhinol Laryngol* **125**, 137, 2016.
28. Valentin, J.E., Turner, N.J., Gilbert, T.W., and Badylak, S.F. Functional skeletal muscle formation with a biologic scaffold. *Biomaterials* **31**, 7475, 2010.
29. Mase, V.J., Jr., Hsu, J.R., Wolf, S.E., Wenke, J.C., Baer, D.G., Owens, J., Badylak, S.F., and Walters, T.J. Clinical application of an acellular biologic scaffold for surgical repair of a large, traumatic quadriceps femoris muscle defect. *Orthopedics* **33**, 511, 2010.
30. Wang, Y., Chen, X., Cao, W., and Shi, Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. *Nat Immunol* **15**, 1009, 2014.
31. Stoltz, J.F., de Isla, N., Li, Y.P., Bensoussan, D., Zhang, L., Huselstein, C., Chen, Y., Decot, V., Magdalou, J., Li, N., Reppel, L., and He, Y. Stem cells and regenerative medicine: myth or reality of the 21st century. *Stem Cells Int* **2015**, 734731, 2015.
32. Caplan, A.I., and Hariri, R. Body management: mesenchymal stem cells control the internal regenerator. *Stem Cells Transl Med* **4**, 695, 2015.
33. Pereira, T., Armada-da Silva, P.A., Amorim, I., Rema, A., Caseiro, A.R., Gartner, A., Rodrigues, M., Lopes, M.A., Bartolo, P.J., Santos, J.D., Luis, A.L., and Mauricio, A.C. Effects of human mesenchymal stem cells isolated from Wharton's jelly of the umbilical cord and conditioned

- media on skeletal muscle regeneration using a myectomy model. *Stem Cells Int* **2014**, 376918, 2014.
34. Choi, J.W., Park, J.K., Chang, J.W., Kim da, Y., Kim, M.S., Shin, Y.S., and Kim, C.H. Small intestine submucosa and mesenchymal stem cells composite gel for scarless vocal fold regeneration. *Biomaterials* **35**, 4911, 2014.
 35. Kim, K.S., Lee, J.Y., Kang, Y.M., Kim, E.S., Kim, G.H., Rhee, S.D., Cheon, H.G., Kim, J.H., Min, B.H., Lee, H.B., and Kim, M.S. Small intestine submucosa sponge for in vivo support of tissue-engineered bone formation in the presence of rat bone marrow stem cells. *Biomaterials* **31**, 1104, 2010.
 36. Lin, H.K., Godiwalla, S.Y., Palmer, B., Frimberger, D., Yang, Q., Madihally, S.V., Fung, K.M., and Kropp, B.P. Understanding roles of porcine small intestinal submucosa in urinary bladder regeneration: identification of variable regenerative characteristics of small intestinal submucosa. *Tissue Eng Part B Rev* **20**, 73, 2014.
 37. Sharma, A.K., Bury, M.I., Marks, A.J., Fuller, N.J., Meisner, J.W., Tapaskar, N., Halliday, L.C., Matoka, D.J., and Cheng, E.Y. A nonhuman primate model for urinary bladder regeneration using autologous sources of bone marrow-derived mesenchymal stem cells. *Stem Cells* **29**, 241, 2011.
 38. Zhang, Q., Shi, S., Liu, Y., Uyanne, J., Shi, Y., Shi, S., and Le, A.D. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. *J Immunol* **183**, 7787, 2009.
 39. Zhang, Q.Z., Nguyen, A.L., Yu, W.H., and Le, A.D. Human oral mucosa and gingiva: a unique reservoir for mesenchymal stem cells. *J Dent Res* **91**, 1011, 2012.
 40. Zhang, Q.Z., Su, W.R., Shi, S.H., Wilder-Smith, P., Xiang, A.P., Wong, A., Nguyen, A.L., Kwon, C.W., and Le, A.D. Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. *Stem Cells* **28**, 1856, 2010.
 41. Zhang, Q., Nguyen, A.L., Shi, S., Hill, C., Wilder-Smith, P., Krasieva, T.B., and Le, A.D. Three-dimensional spheroid culture of human gingiva-derived mesenchymal stem cells enhances mitigation of chemotherapy-induced oral mucositis. *Stem Cells Dev* **21**, 937, 2012.
 42. Shi, L., and Ronfard, V. Biochemical and biomechanical characterization of porcine small intestinal submucosa (SIS): a mini review. *Int J Burns Trauma* **3**, 173, 2013.
 43. Chang, A.C., Dearman, B., and Greenwood, J.E. A comparison of wound area measurement techniques: visitrak versus photography. *Eplasty* **11**, e18, 2011.
 44. Galiano, R.D., Michaels, J.T., Dobryansky, M., Levine, J.P., and Gurtner, G.C. Quantitative and reproducible murine model of excisional wound healing. *Wound Repair Regen* **12**, 485, 2004.
 45. Yeum, C.E., Park, E.Y., Lee, S.B., Chun, H.J., and Chae, G.T. Quantification of MSCs involved in wound healing: use of SIS to transfer MSCs to wound site and quantification of MSCs involved in skin wound healing. *J Tissue Eng Regen Med* **7**, 279, 2013.
 46. Ogura, Y., Hindi, S.M., Sato, S., Xiong, G., Akira, S., and Kumar, A. TAK1 modulates satellite stem cell homeostasis and skeletal muscle repair. *Nat Commun* **6**, 10123, 2015.
 47. Koning, M., Werker, P.M., van Luyn, M.J., and Harmsen, M.C. Hypoxia promotes proliferation of human myogenic satellite cells: a potential benefactor in tissue engineering of skeletal muscle. *Tissue Eng Part A* **17**, 1747, 2011.
 48. Pumberger, M., Qazi, T.H., Ehrentauf, M.C., Textor, M., Kueper, J., Stoltenburg-Didinger, G., Winkler, T., von Roth, P., Reinke, S., Borselli, C., Perka, C., Mooney, D.J., Duda, G.N., and Geissler, S. Synthetic niche to modulate regenerative potential of MSCs and enhance skeletal muscle regeneration. *Biomaterials* **99**, 95, 2016.
 49. Patel, S.A., and Chang, E.I. Principles and practice of reconstructive surgery for head and neck cancer. *Surg Oncol Clin N Am* **24**, 473, 2015.
 50. Lam, L., and Samman, N. Speech and swallowing following tongue cancer surgery and free flap reconstruction—a systematic review. *Oral Oncol* **49**, 507, 2013.
 51. Kordahi, A.M., Hoppe, I.C., and Lee, E.S. A comparison of free tissue transfers to the head and neck performed by surgeons and otolaryngologists. *J Craniofac Surg* **27**, e82, 2016.
 52. Wolf, M.T., Dearth, C.L., Sonnenberg, S.B., Lobo, E.G., and Badylak, S.F. Naturally derived and synthetic scaffolds for skeletal muscle reconstruction. *Adv Drug Deliv Rev* **84**, 208, 2015.
 53. Sicari, B.M., Rubin, J.P., Dearth, C.L., Wolf, M.T., Ambrosio, F., Boninger, M., Turner, N.J., Weber, D.J., Simpson, T.W., Wyse, A., Brown, E.H., Dziki, J.L., Fisher, L.E., Brown, S., and Badylak, S.F. An acellular biologic scaffold promotes skeletal muscle formation in mice and humans with volumetric muscle loss. *Sci Transl Med* **6**, 234ra58, 2014.
 54. Shadrin, I.Y., Khodabukus, A., and Bursac, N. Striated muscle function, regeneration, and repair. *Cell Mol Life Sci* **73**, 4175, 2016.
 55. Wolf, M.T., Daly, K.A., Reing, J.E., and Badylak, S.F. Biologic scaffold composed of skeletal muscle extracellular matrix. *Biomaterials* **33**, 2916, 2012.
 56. Janis, A.D., Johnson, C.C., Ernst, D.M., and Brightman, A.O. Structural characteristics of small intestinal submucosa constructs dictate in vivo incorporation and angiogenic response. *J Biomater Appl* **26**, 1013, 2012.
 57. Nihsen, E.S., Johnson, C.E., and Hiles, M.C. Bioactivity of small intestinal submucosa and oxidized regenerated cellulose/collagen. *Adv Skin Wound Care* **21**, 479, 2008.
 58. Scholl, F.G., Boucek, M.M., Chan, K.C., Valdes-Cruz, L., and Perryman, R. Preliminary experience with cardiac reconstruction using decellularized porcine extracellular matrix scaffold: human applications in congenital heart disease. *World J Pediatr Congenit Heart Surg* **1**, 132, 2010.
 59. Palmer, E.M., Beilfuss, B.A., Nagai, T., Semnani, R.T., Badylak, S.F., and van Seventer, G.A. Human helper T cell activation and differentiation is suppressed by porcine small intestinal submucosa. *Tissue Eng* **8**, 893, 2002.
 60. Allman, A.J., McPherson, T.B., Badylak, S.F., Merrill, L.C., Kallakury, B., Sheehan, C., Raeder, R.H., and Metzger, D.W. Xenogeneic extracellular matrix grafts elicit a Th2-restricted immune response. *Transplantation* **71**, 1631, 2001.
 61. Nihsen, E.S., Zopf, D.A., Ernst, D.M., Janis, A.D., Hiles, M.C., and Johnson, C. Absorption of bioactive molecules into OASIS wound matrix. *Adv Skin Wound Care* **20**, 541, 2007.

62. Hodde, J.P., Ernst, D.M., and Hiles, M.C. An investigation of the long-term bioactivity of endogenous growth factor in OASIS Wound Matrix. *J Wound Care* **14**, 23, 2005.
63. Gneccchi, M., Zhang, Z.P., Ni, A.G., and Dzau, V.J. Paracrine mechanisms in adult stem cell signaling and therapy. *Circ Res* **103**, 1204, 2008.
64. Mirosou, M., Jayawardena, T.M., Schmeckpeper, J., Gneccchi, M., and Dzau, V.J. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. *J Mol Cell Cardiol* **50**, 280, 2011.
65. Wu, Y., Huang, S., Enhe, J., Ma, K., Yang, S., Sun, T., and Fu, X. Bone marrow-derived mesenchymal stem cell attenuates skin fibrosis development in mice. *Int Wound J* **11**, 701, 2014.
66. Maria, A.T., Toupet, K., Maumus, M., Fonteneau, G., Le Quellec, A., Jorgensen, C., Guilpain, P., and Noel, D. Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis. *J Autoimmun* **70**, 31, 2016.
67. Haldar, D., Henderson, N.C., Hirschfield, G., and Newsome, P.N. Mesenchymal stromal cells and liver fibrosis: a complicated relationship. *FASEB J* **30**, 3905, 2016.

Address correspondence to:

Anh D. Le, DDS, PhD

*Department of Oral and Maxillofacial Surgery
and Pharmacology*

University of Pennsylvania School of Dental Medicine

240 South 40th Street

Philadelphia, PA 19104

E-mail: anh.le@uphs.upenn.edu

Bert W. O'Malley Jr., MD

*Department of Otorhinolaryngology—Head
and Neck Surgery*

University of Pennsylvania Perelman School of Medicine

5 Ravdin, 3400 Spruce Street

Philadelphia, PA 19104

E-mail: bert.o'malley@uphs.upenn.edu

Received: August 23, 2016

Accepted: November 9, 2016

Online Publication Date: January 4, 2017